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Background: : Second-line treatment with ramucirumabþFOLFIRI improved overall survival (OS) versus placeboþFOLFIRI for
patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)¼0.84, 95% CI 0.73–0.98, P¼ 0.022]. Post hoc analyses of
RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC
tumour (left versus right) with efficacy parameters.
Patients and methods: Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type.
Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse,
ascending colon, and cecum.
Results: RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for
94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS
mutations (OS HR¼ 0.86, 95% CI 0.71–1.04) and patients with RAS/BRAF wild-type tumours (OS HR¼ 0.86, 95% CI 0.64–1.14).
Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR¼ 0.54, 95% CI 0.25–
1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free
survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P¼ 0.523, PFS P¼ 0.655)
indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small
sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by
2.5 month over placebo (HR¼ 0.81, 95% CI 0.68–0.97); median OS for ramucirumab-treated patients with right-CRC was
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1.1 month over placebo (HR¼ 0.97, 95% CI 0.75–1.26). The treatment-by-sub-group interaction was not statistically significant
for tumour sidedness (P¼ 0.276).
Conclusions: In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF
mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated
tumours, although the P-values were not statistically significant.
ClinicalTrials.gov number: NCT01183780.
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Introduction
The global, randomised, double-blind, placebo-controlled,
RAISE phase III trial examined whether patients with metastatic
colorectal carcinoma (mCRC) who had been previously treated
with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine
would exhibit improved survival when ramucirumab was added
to second-line FOLFIRI (folinic acid, 5-fluorouracil, and irinote-
can) treatment [1]. The human IgG1 monoclonal antibody,
ramucirumab, inhibits tumour angiogenesis by binding to vascu-
lar endothelial growth factor (VEGF) receptor-2 (VEGFR-2) and
interfering with VEGF ligand binding [2]. Results from the
RAISE trial indicated that the addition of ramucirumab to
second-line FOLFIRI improved overall survival (OS) over
placeboþFOLFIRI [median OS 13.3 versus 11.7 months; hazard
ratio (HR)¼0.84; 95% confidence interval (CI) 0.73–0.98;
P¼ 0.022) [1]. Median progression-free survival (PFS) was also
extended by the addition of ramucirumab (5.7 versus 4.5 months,
HR¼ 0.79; 95% CI 0.70–0.90; P< 0.0005) [1].
Analysis of patient sub-groups and biomarkers has aimed to
identify patient or tumour characteristics associated with an
improved ramucirumab benefit. Using an exploratory assay, high
baseline plasma VEGF-D levels (115 pg/ml) were associated
with better survival outcomes for ramucirumab-treated patients
[3]. Low baseline plasma carcinoembryonic antigen (CEA) levels
(10 ng/ml) were also associated with an enhanced ramuciru-
mab response [4]. The KRAS exon 2 mutation is known to affect
CRC response to EGFR inhibitors, but its impact, if any, on
ramucirumab is not known. A pre-specified analysis showed that
both KRAS exon 2 mutant and KRAS exon 2 wild-type tumours
demonstrated a consistent survival benefit in favour of the
ramucirumabþFOLFIRI arm [5]. More recent data demon-
strated that other RAS mutations (KRAS exons 3 and 4, NRAS)
and the BRAF mutation also reduce benefit from anti-EGFR
therapies [6]; therefore, the impact of these mutations on ramu-
cirumab efficacy must be examined as well.
In addition to the possible impact of gene mutations, evidence
indicates that the location of the primary CRC has prognostic
implications and may be predictive of response to anti-EGFR
therapy [7, 8]. This phenomenon may be explained in part by the
different embryologic origin of the left and right colon and the re-
sultant anatomical, histological, molecular, and environmental
differences that impact tumours arising along its length [7].
Given evidence that additional RAS/RAF mutations and tu-
mour sidedness impact EGFR-directed treatment, we undertook
retrospective analyses of the association of these parameters and
the efficacy of the VEGFR inhibitor, ramucirumab, using data
from the RAISE phase III clinical trial.
Methods
Study design
The design of the RAISE phase III trial (ClinicalTrials.gov,
NCT01183780) has been reported [1]. In brief, eligible patients had
pathologically confirmed mCRC that had progressed during first-line
treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine or
within 6 months of the last dose of first-line therapy. Patients were rando-
mised (1 : 1) to ramucirumab or placebo, with stratification by geography
(North America versus Europe versus all other regions), KRAS exon 2
status (wild-type versus mutant), and time to first-line disease progres-
sion (6 versus <6 months). Ramucirumab (8 mg/kg) or placebo was
administered on day 1 of each 2-week cycle, followed by FOLFIRI for
both treatment arms. Treatment cycles were continued until disease pro-
gression, decision by physician or patient, toxicity, or death.
Tumour tissue collection was undertaken for all study participants.
In samples reported locally as KRAS wild-type, further RAS (KRAS
exon 3 or 4 mutation, NRAS exon 2, 3, or 4 mutation) and BRAF muta-
tions were assessed centrally by multiplex qPCR using the Modaplex
system (Qiagen) for patients who had sufficient tumour remaining
after other biomarker testing [3] was carried out. Patients were classi-
fied into one of the three following categories: BRAF mutant, KRAS/
NRAS mutant (RAS mutant), or wild-type for KRAS/NRAS/BRAF
(RAS/BRAF wild-type).
Pre-treatment levels of plasma VEGF-D were assessed using an ex-
ploratory dual-monoclonal sandwich immunoassay and categorised as
high/low (115 pg/ml threshold) as previously described [3].
Sidedness data were collected for each patient. Patients were
designated as left CRC with primary tumours originating in the splenic
flexure, descending and sigmoid colon, or rectum; and as right
CRC with tumours originating in transverse or ascending colon and
cecum [7].
Statistical analyses
OS and PFS were evaluated by RAS/RAF and tumour sidedness sub-
groups using the Kaplan–Meier method. The unstratified Cox propor-
tional hazards model was used to estimate HR and 95% CI. The study
stratification factors were used as covariates in the RAS/RAF sub-group
Cox models. For both OS and PFS, treatment-by-sub-group interaction
was examined using the likelihood ratio test. P-values were not adjusted
for multiple comparisons.
Results
Among the 1072 patients randomised to a treatment arm for the
RAISE trial [intent-to-treat (ITT) population], RAS/RAF mutation
status was available for 912 (85%), and primary tumour location
was known for 1012 patients (94%). RAS mutations were found in
63% of patients (579/912); BRAF mutation in 4.5% (41/912, all
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V600E positive); 32% of patients were RAS/BRAF wild-type
(292/912) (see flowchart of supplementary Figure S1 and Table
S1, available at Annals of Oncology online for details). Within
RAS/BRAF wild-type and RAS mutant sub-groups (Table 1),
baseline characteristics were balanced between treatment arms,
although the RAS/BRAF wild-type placebo arm had more males
(71% versus 55%) and patients with>10 ng/ml CEA (68% versus
60%) than the ramucirumab arm. Within the 41-patient BRAF
mutant sub-group, treatment arms were relatively balanced.
BRAF mutations were more prevalent in right-sided tumours.
Among the tumour sidedness sub-groups, left CRC predomi-
nated (69%, 699/1012) (supplementary Table S2, available at
Annals of Oncology online). Within left versus right sub-groups,
baseline patient and tumour characteristics were largely balanced
between treatment arms. The left sub-group had a lower percent-
age of females (40% versus 48%) than the right.
Table 1. Summary of patient and disease characteristics in the RAS/RAF mutation sub-groups



















n (%) n (%) n (%) n (%) n (%) n (%)
Age group
65 years 58 (39) 63 (44) 128 (45) 112 (38) 6 (30) 10 (48)
70 years 27 (18) 33 (23) 65 (23) 70 (24) 4 (20) 6 (29)
Gender
Male 82 (55) 102 (71) 150 (53) 161 (55) 12 (60) 12 (57)
Female 67 (45) 41 (29) 135 (47) 133 (45) 8 (40) 9 (43)
Geographical region
Japan/East Asia 33 (22) 32 (22) 54 (19) 45 (15) 2 (10) 1 (5)
Rest of world 116 (78) 111 (78) 231 (81) 249 (85) 18 (90) 20 (95)
Race
Black 5 (3) 2 (1) 9 (3) 10 (3) 0 1 (5)
Other 35 (23) 37 (26) 57 (20) 48 (16) 4 (20) 2 (10)
White 108 (72) 103 (72) 219 (77) 234 (80) 16 (80) 17 (81)
Missing 1 (1) 1 (1) 0 2 (1) 0 1 (5)
ECOG PS
0 80 (54) 72 (50) 142 (50) 147 (50) 13 (65) 11 (52)
1 69 (46) 71 (50) 143 (50) 146 (50) 6 (30) 10 (48)
Missing 0 0 0 1 (<1) 1 (5) 0
Time to progression after first-line
<6 months 40 (27) 37 (26) 64 (22) 66 (22) 7 (35) 11 (52)
6 months 109 (73) 106 (74) 221 (78) 228 (78) 13 (65) 10 (48)
Colorectal tumour sidedness
Left 110 (74) 108 (76) 178 (62) 175 (60) 7 (35) 6 (29)
Right 29 (19) 27 (19) 95 (33) 99 (34) 11 (55) 14 (67)
Missing 10 (7) 8 (6) 12 (4) 20 (7) 2 (10) 1 (5)
Baseline plasma VEGF-D levelb
High 79 (53) 83 (58) 143 (50) 133 (45) 13 (65) 14 (67)
Low 43 (29) 44 (31) 97 (34) 100 (34) 5 (25) 3 (14)
Missing 27 (18) 16 (11) 45 (16) 61 (21) 2 (10) 4 (19)
Baseline plasma CEA level
>10 ng/ml 90 (60) 97 (68) 195 (68) 196 (67) 13 (65) 9 (43)
10 ng/ml 44 (30) 38 (27) 76 (27) 80 (27) 7 (35) 11 (52)
200 ng/ml 23 (15) 26 (18) 63 (22) 64 (22) 3 (15) 2 (10)
<200 ng/ml 111 (75) 109 (76) 208 (73) 212 (72) 17 (85) 18 (86)
Missing 15 (10) 9 (6) 14 (5) 18 (6) 0 1 (5)
aA single patient was found to have mutations in both RAS and BRAF; this patient was included only in the BRAF mutant sub-group for all summaries and
analyses and in the counts listed above.
bVEGF-D high 115 pg/ml; VEGF-D low <115 pg/ml.
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, folinic acid, 5-fluorouracil and irinotecan; PS, performance status;
VEGF, vascular endothelial growth factor.
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A favourable ramucirumab treatment effect was found in the
RAS/BRAF wild-type sub-group and the RAS mutant sub-group.
Ramucirumab treatment was associated with prolonged OS
(HR< 1) for the RAS/BRAF wild-type sub-group (median 16.2
versus 15.5 months; HR¼ 0.86, 95% CI 0.64–1.14) and the RAS
mutant sub-group (median 12.9 versus 11.5 months; HR¼ 0.86,
95% CI 0.71–1.04) (Figure 1A and C; Table 2). A similar trend
was observed with PFS for both the RAS mutant and RAS/BRAF
Figure 1. Kaplan–Meier curves of OS and PFS in RAS/RAF sub-groups. OS (A, C, E) and PFS (B, D, F) were calculated using Kaplan–Meier plots
of RAISE RAS/BRAF wild-type (A, B), RAS mutant (C, D), and BRAF mutant (E, F) populations. HRs and 95% CI were estimated from an unstrati-
fied Cox model adjusted for covariates (stratification factors).
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wild-type sub-group (Figure 1B and D; Table 2). Treatment-by-
mutation status interaction tests indicated that the ramucirumab
benefit was not statistically different among the three mutation
status sub-groups (OS P¼ 0.523, PFS P¼ 0.655).
Analysis of the Kaplan–Meier plots of the BRAF mutant sub-
group showed that ramucirumabþFOLFIRI treatment appears
to substantially benefit patients harbouring BRAF-mutated
tumours. Ramucirumab-treated patients exhibited a non-
statistically significant OS and PFS benefit over placebo (median
OS 9.0 versus 4.2 months, HR¼ 0.54, 95% CI 0.25–1.13; median
PFS 5.7 versus 2.7 months, HR¼ 0.55, 95% CI 0.28–1.08)
(Figure 1E and F; Table 2); although this analysis is limited by
sample size. The RAS/RAF sub-groups showed no substantial dif-
ference between arms in post-discontinuation treatment that
may have differentially impacted survival (supplementary Table
S3, available at Annals of Oncology online).
Since high VEGF-D levels from an exploratory assay seem to
suggest a greater benefit with ramucirumab, we examined base-
line VEGF-D expression in RAS/RAF mutation sub-groups and
its association with treatment effects. When treated as a con-
tinuous variable, there was no evidence suggesting different
VEGF-D expression among the RAS/BRAF wild-type, RAS mu-
tant, and BRAF mutant sub-groups (P¼ 0.358), although BRAF
mutant population had a slightly higher percentage of patients
classified as having high VEGF-D (Table 1). Treatment effects in
the RAS/RAF mutation sub-groups by baseline plasma VEGF-D
levels showed that RAS mutants with high baseline VEGF-D lev-
els (n¼ 276) benefitted from ramucirumab with statistically sig-
nificantly higher OS (HR¼ 0.64, 95% CI 0.49–0.84, P¼ 0.0014)
and PFS (HR¼ 0.54, 95% CI 0.42–0.70, P< 0.0001) (supple-
mentary Table S4, available at Annals of Oncology online). In
contrast, patients with RAS mutations with low baseline VEGF-
D (n¼ 197) exhibited no ramucirumab benefit but rather OS
and PFS favoured the placebo arm. The RAS/BRAF wild-type
sub-group behaved similarly to the RAS mutant sub-group.
Patients with high baseline VEGF-D exhibited a significant PFS
benefit from ramucirumab (although no OS benefit was
observed), and the low VEGF-D sub-group displayed no benefit
from ramucirumab (supplementary Table S4, available at
Annals of Oncology online). The small number of patients in the
BRAF mutation sub-group precluded conclusions regarding ef-
fect of ramucirumab by VEGF-D level. Stem-and-leaf plots were
constructed to examine data distribution by baseline VEGF-D
level (supplementary Figure S2, available at Annals of Oncology
online). In patients with BRAF mutations, there was no indica-
tion of a differential ramucirumab benefit in patients by VEGF-
D level.
The treatment effect of ramucirumabþFOLFIRI by tumour
sidedness was also evaluated. Ramucirumab-treated patients
with left-sided tumours exhibited improved OS (HR¼ 0.81, 95%
CI 0.68–0.97), with median OS increasing 2.5 months for ramu-
cirumab over placebo (14.5 versus 12.0 months) (Figure 2A;
Table 2). Patients with right CRC tumours also exhibited a direc-
tional ramucirumab survival benefit on aggregate, but of smaller
magnitude, with a 1.1-month increase in median OS (12.7 versus
11.6 months, HR¼ 0.97, 95% CI 0.75–1.26) (Figure 2C; Table 2).
The interaction P-value was not statistically significant (0.276),
indicating that sidedness is not predictive of the efficacy of adding
ramucirumab to FOLFIRI in these analyses. A similar trend was
observed with PFS (Figure 2B and D); the interaction P-value was
again not significant (0.578).
There was no association between VEGF-D levels and sided-
ness (supplementary Table S5, available at Annals of Oncology on-
line); the ramucirumab benefit in patients with high VEGF-D
levels was seen in both right- and left-sided tumours (supplemen-
tary Table S6, available at Annals of Oncology online). There was
no substantial difference among the sidedness sub-groups in
post-discontinuation treatment that likely would have impacted
Table 2. Summary of sub-group analyses of overall survival and progression-free survival by RAS/RAF mutation status and tumour sidedness















RAS/BRAF wild-typec Ramucirumab 149 16.2 0.86 (0.64–1.14) P¼0.2899 0.523 5.7 0.78 (0.61–1.00) P¼0.0512 0.655
Placebo 143 15.5 5.7
RAS mutantc Ramucirumab 285 12.9 0.86 (0.71–1.04) P¼0.1110 5.7 0.81 (0.68–0.97) P¼0.0209
Placebo 294 11.5 4.3
BRAF mutantc Ramucirumab 20 9.0 0.54 (0.25–1.13) P¼0.1030 5.7 0.55 (0.28–1.08) P¼0.0826
Placebo 21 4.2 2.7
Left-sided CRC Ramucirumab 353 14.5 0.81 (0.68–0.97) P¼0.0188 0.276 6.0 0.78 (0.66–0.91) P¼0.0014 0.578
Placebo 346 12.0 4.4
Right-sided CRC Ramucirumab 154 12.7 0.97 (0.75–1.26) P¼0.8242 5.6 0.86 (0.67–1.08) P¼0.1955
Placebo 159 11.6 4.5
aBoth ramucirumab and placebo were given in combination with FOLFIRI.
bLikelihood ratio.
cRAS/RAF analyses adjusted for stratification factors as covariates.
CI, confidence interval; CRC, colorectal carcinoma; FOLFIRI, folinic acid, 5-fluorouracil and irinotecan; HR, hazard ratio.
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survival results (supplementary Table S7, available at Annals of
Oncology online).
Discussion
Analyses of mCRC trials have revealed that the RAS/RAF gene
mutation profile and tumour sidedness are both determinants of
patient prognosis and have bearing on anti-EGFR treatment effi-
cacy in first-line trials [9, 10]. Published data on the impact of tu-
mour sidedness and RAS/RAF mutations on the efficacy of
antiangiogenic therapy is limited, especially in the second-line
setting. Our exploratory retrospective analyses of the RAISE
phase III trial data examined whether RAS/RAF mutation status
and tumour sidedness influenced the antiangiogenic treatment
efficacy of ramucirumab in patients with mCRC that progressed
during or after a first-line treatment with bevacizumab, oxalipla-
tin, and a fluoropyrimidine. While these exploratory analyses are
limited because they are retrospective and may be underpowered,
they are useful indicators of areas to investigate more completely.
Analysis of patients with RAS mutations in the RAISE trial
showed these mutations were associated with a worse prognosis
than the RAS/BRAF wild-type. Other studies have made a similar
observation [10]. Consistent with the prior RAISE analysis, this
analysis showed ramucirumab added to FOLFIRI improved pa-
tient outcomes over placebo regardless of RAS mutation status.
The ramucirumab benefit to patients with KRAS/NRAS mutation
could not be ascribed to an imbalance between treatment arms in
baseline characteristics, including any imbalance in VEGF-D and
CEA baseline plasma levels. However, it was noteworthy that
both RAS mutant patients and RAS/BRAF wild-type patients
with high baseline VEGF-D levels displayed a more robust re-
sponse to ramucirumab treatment than those with low VEGF-D
levels, suggesting the predictive value of VEGF-D is independent
of the RAS mutation status.
In agreement with other studies [10], the RAISE data showed
that the BRAF mutation was present in a low percentage of
patients with CRC (4.5%) and occurred more frequently in right-
sided tumours. Patients with the BRAF mutation had worse sur-
vival than patients who were RAS/BRAF wild-type, irrespective of
Figure 2. Kaplan–Meier curves of OS and PFS in left and right CRC sub-groups. OS (A, C) and PFS (B, D) were determined using Kaplan–
Meier plots of RAISE ITT patients with left (A, B) and right (C, D) CRC. HRs and 95% CI were estimated from an unstratified Cox model with
treatment group as the only covariate. Tick marks represent censored events.
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treatment received, confirming BRAF as a negative prognostic
factor in the second-line setting. Patients with the BRAF muta-
tion appeared to benefit from ramucirumab over placebo (OS
HR¼ 0.54, 95% CI 0.25–1.13; PFS HR¼ 0.55, 95% CI 0.28–
1.08), with median OS and PFS more than double the placebo
medians. This result could not be explained by an imbalance be-
tween treatment arms in patients with low baseline CEA levels or
high baseline VEGF-D levels (Table 1), two variables associated
with better ramucirumab efficacy. However, the sample size was
too small to make any firm determination about whether there is
a real difference in effect in the BRAF-mutant patients versus the
RAS/BRAF wild-type or RAS mutant populations. Currently,
there is no strong biological rationale for a greater ramucirumab
benefit in patients with BRAF-mutated mCRC.
The ramucirumab benefit in BRAF mutant tumours may differ
from that of the anti-EGFR monoclonal antibodies, cetuximab
and panitumumab, which appear to have minimal benefit in
first-line trials, and a suggestion of harm in one second-line trial
(PICCOLO) [10, 11]. The indication of a potentially increased
ramucirumab benefit observed with BRAF-mutated cancers in
the RAISE trial was of interest given the poor prognosis of BRAF
mutant CRC. These findings are consistent with the VELOUR
trial biomarker analysis [12, 13] that analyzed 482 samples from
1226 randomised patients (39% of the patients) in a similar set-
ting: patients with second-line mCRC that progressed after
oxaliplatin-based chemotherapy. The trial randomised afliber-
cept, a fusion protein that binds circulating VEGF-A, VEGF-B,
and PlGF, versus placebo, both in combination with FOLFIRI
chemotherapy. The BRAF-mutated population (n¼ 36, 7.5%)
had a numerically stronger benefit with the aflibercept treatment
(OS HR¼ 0.42, 95% CI 0.16–1.09) compared with the aflibercept
treatment effect observed in the RAS wild-type, RAS mutant, and
ITT population.
Analysis of primary tumour sidedness distribution in the
RAISE trial showed 69% of patients had left-sided tumours and
31% had right-sided. This left-right ratio is comparable to what
has been observed in other studies [9, 14]. The left tumour sub-
group had a lower percentage of females and mutant RAS
tumours than the right tumour sub-group, consistent with previ-
ously published data [7, 15].
Examination of the survival benefit associated with tumour lo-
cation revealed patients with left-sided CRC tumours exhibited a
significant OS benefit from ramucirumab (2.5 months,
HR¼ 0.81, P¼ 0.0188). The improvement in median OS for
patients with right-sided CRC tumours receiving ramucirumab
was lesser (1.1 months) and not statistically significant
(HR¼ 0.97, P¼ 0.8242) in this smaller patient sub-group. The
PFS results followed the same trend. While the non-significant
interaction test for both end points (OS P¼ 0.276; PFS
P¼ 0.578) suggests a lack of evidence for different ramucirumab
efficacy according to primary tumour site of origin, confirmation
of this result would require an appropriately powered, prospect-
ively planned study.
Response to ramucirumab by both patients with left- and
right-sided CRC tumours is similar to reported results with beva-
cizumab in first-line studies [16, 17] and in the maintenance AIO
0207 study [18]. The AIO 0207 study compared fluoropyrimi-
dine plus bevacizumab, bevacizumab alone, and no treatment
following 24 weeks of standard induction chemotherapy.
Tumour sidedness acted as a strong prognostic factor, but the
antiangiogenic benefit was seen on both sides, with a numerically
superior antiangiogenic benefit in patients with left-sided
tumours. The second-line mCRC VELOUR study also found that
addition of an antiangiogenic was efficacious for left- and right-
sided tumours [13].
The efficacy of EGFR inhibitors appears to be limited by tumour
sidedness. Studies have identified that left CRC tumours seem to
be responsive to anti-EGFR therapy (cetuximab, panitumumab),
but right-sided tumours are not [14, 19, 20]. Therefore, treatment
guidelines currently recommend using these agents only in
tumours originating from the left side of the colon [21, 22].
In conclusion, exploratory retrospective analyses of RAISE trial
data have shown ramucirumab treatment is effective in a second-
line setting, regardless of RAS/RAF mutation status and tumour
sidedness. While the EGFR inhibitor treatments appear more cir-
cumscribed in their effective usage, ramucirumab is effective for
patients with mutant RAS or BRAF tumours and patients who are
RAS/BRAF wild-type. Of interest, evidence was found that
patients with BRAF mutant tumours have a potentially increased
benefit with ramucirumab, but the relationship was not signifi-
cant in this small sub-population and requires further validation.
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